CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates

Tatsuo Kawai, Hiroshi Sogawa, Svetlan Boskovic, Gregory Abrahamian, Rex Neal Smith, Siew Lin Wee, David Andrews, Ognjenka Nadazdin, Ichiro Koyama, Megan Sykes, Henry J. Winn, Robert B. Colvin, David H. Sachs, A. Benedict Cosimi

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

Costimulatory blockade with anti-CD154 monoclonal antibody (aCD154) prolongs allograft survival in non-human primates, but has not reliably induced tolerance when used alone. In the current studies, we evaluated the effect of adding CD154 blockade to a chimerism inducing nonmyeloablative regimen in primates. We observed a significant improvement of donor bone marrow (DBM) engraftment, which has been associated with a lower incidence of acute rejection and long-term survival of renal allografts without the need for previously required splenectomy. Among the long-term survivors, four never showed evidence of rejection, with the longest survival exceeding 1700 days following discontinuation of immunosuppression. Nevertheless, late chronic rejection was observed in three of eight recipients, indicating the necessity of further modifications of the regimen. Control recipients receiving no DBM or donor splenocytes in place of DBM rejected their allografts. Thus, DBM engraftment with, at least, transient mixed chimerism appears essential for induction of allograft tolerance using this conditioning regimen. Modification of the original mixed chimerism approach, by the addition of costimulatory blockade, has been shown to enhance mixed chimerism and induce renal allograft tolerance with less morbidity in nonhuman primates.

Original languageEnglish
Pages (from-to)1391-1398
Number of pages8
JournalAmerican Journal of Transplantation
Volume4
Issue number9
DOIs
StatePublished - Sep 1 2004
Externally publishedYes

Fingerprint

Chimerism
Primates
Allografts
Tissue Donors
Kidney
Bone Marrow
Transplantation Tolerance
Splenectomy
Immunosuppression
Survivors
Monoclonal Antibodies
Morbidity
Survival
Incidence

Keywords

  • CD154 blockade
  • Kidney transplantation
  • Mixed chimerism
  • Tolerance

ASJC Scopus subject areas

  • Immunology

Cite this

CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. / Kawai, Tatsuo; Sogawa, Hiroshi; Boskovic, Svetlan; Abrahamian, Gregory; Smith, Rex Neal; Wee, Siew Lin; Andrews, David; Nadazdin, Ognjenka; Koyama, Ichiro; Sykes, Megan; Winn, Henry J.; Colvin, Robert B.; Sachs, David H.; Cosimi, A. Benedict.

In: American Journal of Transplantation, Vol. 4, No. 9, 01.09.2004, p. 1391-1398.

Research output: Contribution to journalArticle

Kawai, T, Sogawa, H, Boskovic, S, Abrahamian, G, Smith, RN, Wee, SL, Andrews, D, Nadazdin, O, Koyama, I, Sykes, M, Winn, HJ, Colvin, RB, Sachs, DH & Cosimi, AB 2004, 'CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates', American Journal of Transplantation, vol. 4, no. 9, pp. 1391-1398. https://doi.org/10.1111/j.1600-6143.2004.00523.x
Kawai, Tatsuo ; Sogawa, Hiroshi ; Boskovic, Svetlan ; Abrahamian, Gregory ; Smith, Rex Neal ; Wee, Siew Lin ; Andrews, David ; Nadazdin, Ognjenka ; Koyama, Ichiro ; Sykes, Megan ; Winn, Henry J. ; Colvin, Robert B. ; Sachs, David H. ; Cosimi, A. Benedict. / CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. In: American Journal of Transplantation. 2004 ; Vol. 4, No. 9. pp. 1391-1398.
@article{d7682c6fccdc46d594034a9d08d0befe,
title = "CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates",
abstract = "Costimulatory blockade with anti-CD154 monoclonal antibody (aCD154) prolongs allograft survival in non-human primates, but has not reliably induced tolerance when used alone. In the current studies, we evaluated the effect of adding CD154 blockade to a chimerism inducing nonmyeloablative regimen in primates. We observed a significant improvement of donor bone marrow (DBM) engraftment, which has been associated with a lower incidence of acute rejection and long-term survival of renal allografts without the need for previously required splenectomy. Among the long-term survivors, four never showed evidence of rejection, with the longest survival exceeding 1700 days following discontinuation of immunosuppression. Nevertheless, late chronic rejection was observed in three of eight recipients, indicating the necessity of further modifications of the regimen. Control recipients receiving no DBM or donor splenocytes in place of DBM rejected their allografts. Thus, DBM engraftment with, at least, transient mixed chimerism appears essential for induction of allograft tolerance using this conditioning regimen. Modification of the original mixed chimerism approach, by the addition of costimulatory blockade, has been shown to enhance mixed chimerism and induce renal allograft tolerance with less morbidity in nonhuman primates.",
keywords = "CD154 blockade, Kidney transplantation, Mixed chimerism, Tolerance",
author = "Tatsuo Kawai and Hiroshi Sogawa and Svetlan Boskovic and Gregory Abrahamian and Smith, {Rex Neal} and Wee, {Siew Lin} and David Andrews and Ognjenka Nadazdin and Ichiro Koyama and Megan Sykes and Winn, {Henry J.} and Colvin, {Robert B.} and Sachs, {David H.} and Cosimi, {A. Benedict}",
year = "2004",
month = "9",
day = "1",
doi = "10.1111/j.1600-6143.2004.00523.x",
language = "English",
volume = "4",
pages = "1391--1398",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates

AU - Kawai, Tatsuo

AU - Sogawa, Hiroshi

AU - Boskovic, Svetlan

AU - Abrahamian, Gregory

AU - Smith, Rex Neal

AU - Wee, Siew Lin

AU - Andrews, David

AU - Nadazdin, Ognjenka

AU - Koyama, Ichiro

AU - Sykes, Megan

AU - Winn, Henry J.

AU - Colvin, Robert B.

AU - Sachs, David H.

AU - Cosimi, A. Benedict

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Costimulatory blockade with anti-CD154 monoclonal antibody (aCD154) prolongs allograft survival in non-human primates, but has not reliably induced tolerance when used alone. In the current studies, we evaluated the effect of adding CD154 blockade to a chimerism inducing nonmyeloablative regimen in primates. We observed a significant improvement of donor bone marrow (DBM) engraftment, which has been associated with a lower incidence of acute rejection and long-term survival of renal allografts without the need for previously required splenectomy. Among the long-term survivors, four never showed evidence of rejection, with the longest survival exceeding 1700 days following discontinuation of immunosuppression. Nevertheless, late chronic rejection was observed in three of eight recipients, indicating the necessity of further modifications of the regimen. Control recipients receiving no DBM or donor splenocytes in place of DBM rejected their allografts. Thus, DBM engraftment with, at least, transient mixed chimerism appears essential for induction of allograft tolerance using this conditioning regimen. Modification of the original mixed chimerism approach, by the addition of costimulatory blockade, has been shown to enhance mixed chimerism and induce renal allograft tolerance with less morbidity in nonhuman primates.

AB - Costimulatory blockade with anti-CD154 monoclonal antibody (aCD154) prolongs allograft survival in non-human primates, but has not reliably induced tolerance when used alone. In the current studies, we evaluated the effect of adding CD154 blockade to a chimerism inducing nonmyeloablative regimen in primates. We observed a significant improvement of donor bone marrow (DBM) engraftment, which has been associated with a lower incidence of acute rejection and long-term survival of renal allografts without the need for previously required splenectomy. Among the long-term survivors, four never showed evidence of rejection, with the longest survival exceeding 1700 days following discontinuation of immunosuppression. Nevertheless, late chronic rejection was observed in three of eight recipients, indicating the necessity of further modifications of the regimen. Control recipients receiving no DBM or donor splenocytes in place of DBM rejected their allografts. Thus, DBM engraftment with, at least, transient mixed chimerism appears essential for induction of allograft tolerance using this conditioning regimen. Modification of the original mixed chimerism approach, by the addition of costimulatory blockade, has been shown to enhance mixed chimerism and induce renal allograft tolerance with less morbidity in nonhuman primates.

KW - CD154 blockade

KW - Kidney transplantation

KW - Mixed chimerism

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=4344586455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344586455&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2004.00523.x

DO - 10.1111/j.1600-6143.2004.00523.x

M3 - Article

VL - 4

SP - 1391

EP - 1398

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 9

ER -